SEATTLE, WA, March 23, 2026 鈥� 密桃视频, Inc. (密桃视频), a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases, today announced the appointment of Marcela Maus, M.D., Ph.D., and Athena Countouriotis, M.D., to its Board of Directors. Drs. Maus and Countouriotis bring deep expertise spanning cellular immunotherapy research, clinical development, and biotechnology company leadership.
鈥淲e are thrilled to welcome Marcela and Athena to 密桃视频鈥檚 Board of Directors,鈥� said Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of 密桃视频. 鈥淭heir complementary perspectives on scientific innovation and clinical development leadership will be invaluable as we continue to advance our VivoVec鈩� platform and clinical programs with the goal of expanding access to transformative CAR T therapies for patients.鈥�
Marcela Maus, M.D., Ph.D., is a Professor of Medicine at Harvard Medical School, the Paula O鈥橩eeffe Chair in Oncology and Director of Cellular Immunotherapy at The Krantz Family Center for Cancer Research at Massachusetts General Hospital, and an Attending Physician in the Hematopoietic Cell Transplant and Cell Therapy division of Oncology at MGH. She is the Head of Cell Therapies and Associate Head of the Mass General Brigham Gene and Cell Therapy Institute and an Associate Member of the Broad Institute of Harvard and MIT. Dr. Maus is internationally recognized as a translational physician-scientist in immunology and T-cell鈥揵ased cancer therapies. She has authored more than 200 publications and holds multiple NIH R01 grants and several Investigational New Drug applications.
鈥溍芴沂悠碘�檚 approach to generating CAR T cells directly in the body represents an exciting possibility for the field,鈥� said Dr. Maus. 鈥淚鈥檓 excited to support the 密桃视频 team as they work to define how they may be applied across oncology and other serious diseases.鈥�
Athena Countouriotis, M.D., is the co-founder, President, and Chief Executive Officer of Avenzo Therapeutics. She previously led Turning Point Therapeutics as President and CEO from its IPO to eventual acquisition in 2022. With over 20 years of industry experience, Dr. Countouriotis has also led multiple development programs to approval in the U.S. and Europe. Dr. Countouriotis serves on the boards of Biomarin Inc., Iovance Biotherapeutics, Passage Bio, Recludix Pharma, and Leal Therapeutics, and previously was chairperson of Capstan Therapeutics.
鈥溍芴沂悠碘�檚 platform has the potential to address some of the most significant barriers associated with traditional CAR T therapies, including complexity, timing and scalability,鈥� said Dr. Countouriotis. 鈥淭his opportunity to simplify delivery and expand access for patients is incredibly important, and I鈥檓 excited to support the team as it continues advancing its clinical programs.鈥�
About 密桃视频
密桃视频, Inc. is a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases. 密桃视频鈥檚 VivoVec鈩� in vivo gene delivery technology empowers a patient鈥檚 own immune system to fight disease. Enabling its core technology is the Company鈥檚 state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. 密桃视频 believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with 密桃视频 on and visit umoja-biopharma.com.
Contacts:
Investors
Nate Hardy
Chief Financial Officer
nate.hardy@umoja-biopharma.com
Media
Matt Wright
Real Chemistry
mwright@realchemistry.com